SODIUM CHLORIDE INJECTION 0.9% 20 mL ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

sodium chloride injection 0.9% 20 ml ampoule

interpharma pty ltd - sodium chloride, quantity: 9 mg/ml - injection, solution - excipient ingredients: water for injections - sodium chloride injection bp 0.9% can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid. it can also be used as a sterile irrigation medium.

SODIUM CHLORIDE INJECTION 0.9% 5 mL ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

sodium chloride injection 0.9% 5 ml ampoule

interpharma pty ltd - sodium chloride, quantity: 9 mg/ml - injection, solution - excipient ingredients: water for injections - sodium chloride injection bp 0.9% can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid. it can also be used as a sterile irrigation medium.

SODIUM CHLORIDE INJECTION 0.9% 10 mL ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

sodium chloride injection 0.9% 10 ml ampoule

interpharma pty ltd - sodium chloride, quantity: 9 mg/ml - injection, solution - excipient ingredients: water for injections - sodium chloride injection bp 0.9% can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid. it can also be used as a sterile irrigation medium.

MZ Clonidine HCl Injection clonidine hydrochloride 150 microgram/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

mz clonidine hcl injection clonidine hydrochloride 150 microgram/1 ml solution for injection ampoule

medsurge pharma pty ltd - clonidine hydrochloride, quantity: 150 microgram/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - mz clonidine hcl injection is indicated for acute hypertensive crisis and as an alternative to oral therapy where the oral route of administration is inappropriate.

AMIODARONE JUNO amiodarone hydrochloride 150mg/3mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

amiodarone juno amiodarone hydrochloride 150mg/3ml solution for injection ampoule

juno pharmaceuticals pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; water for injections; benzyl alcohol; hydrochloric acid; sodium hydroxide - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachyardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.,amiodarone hhh injection may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. amiodarone hhh injection should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise.

AMIODARONE GH INJECTION amiodarone hydrochloride 150mg/3mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

amiodarone gh injection amiodarone hydrochloride 150mg/3ml solution for injection ampoule

juno pharmaceuticals pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; benzyl alcohol; water for injections; hydrochloric acid; sodium hydroxide - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachyardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.,amiodarone gh injection may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. amiodarone gh injection should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise.

BACTHECAL baclofen 10 mg/5 mL intrathecal solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 10 mg/5 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

BACTHECAL baclofen 10 mg/20 mL intrathecal solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 10 mg/20 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

BACTHECAL baclofen 0.05 mg/1 mL intrathecal solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 0.05 mg/1 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 0.05 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

B. BRAUN FENTANYL fentanyl (as citrate) 500 micrograms/10 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun fentanyl fentanyl (as citrate) 500 micrograms/10 ml solution for injection ampoule

b braun australia pty ltd - fentanyl citrate, quantity: 785 microgram (equivalent: fentanyl, qty 500 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections - analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises - use as an opioid analgesic supplement in general and regional anaesthesia - administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.